Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Diabetic Macular Edema · Hypercholesterolemia · REGN

Regeneron UK

Regeneron UK Limited

Regeneron UK clinical programs — 493 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Tarrytown, USA HQ
16,715 Employees
Public company Type
REGN · NYSE Ticker
Company details
Status
Public
HQ
Tarrytown, USA
Employees
16,715
Programs
493
Drugs
98
Patents
837
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Regeneron UK projects

493 ClinicalTrials.gov programs sponsored by Regeneron UK.

Regeneron UK has 493 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

493 programs

Clinical programs

Page 3 of 11

  1. Ranibizumab

    Regeneron UK Limited

    Macular Degeneration

    phase 3 small molecule completed

    2 trials

  2. Ravulizumab

    Regeneron UK Limited

    Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule active

    1 trial

  3. Rilonacept

    Regeneron UK Limited

    Acute Gout Flare

    phase 3 small molecule completed

    1 trial

  4. Rilonacept

    Regeneron UK Limited

    Gout

    phase 3 mab completed

    3 trials

  5. Rilonacept 80 mg

    Regeneron UK Limited

    Intercritical Gout

    phase 3 small molecule completed

    1 trial

  6. SAR153191 (REGN88)

    Regeneron UK Limited

    Rheumatoid Arthritis

    phase 3 small molecule completed

    2 trials

  7. Sarilumab

    Regeneron UK Limited

    COVID-19

    phase 3 small molecule completed

    1 trial

  8. Sarilumab

    Regeneron UK Limited

    RA

    phase 3 small molecule completed

    1 trial

  9. Sarilumab SAR153191

    Regeneron UK Limited

    Giant Cell Arteritis

    phase 3 small molecule terminated

    1 trial

  10. Sarilumab SAR153191

    Regeneron UK Limited

    Corona Virus Infection

    phase 3 small molecule completed

    1 trial

  11. Sarilumab SAR153191 (REGN88)

    Regeneron UK Limited

    Polymyalgia Rheumatica

    phase 3 small molecule terminated

    1 trial

  12. Suptavumab 30 mg/kg

    Regeneron UK Limited

    Respiratory Syncytial Virus Infections

    phase 3 small molecule completed

    1 trial

  13. VEGF Trap-Eye (BAY86-5321)

    Regeneron UK Limited

    Macular Edema

    phase 3 mab completed

    1 trial

  14. VEGF Trap-Eye (BAY86-5321)

    Regeneron UK Limited

    Diabetes Mellitus

    phase 3 mab completed

    1 trial

  15. VEGF Trap-Eye (BAY86-5321)

    Regeneron UK Limited

    Myopia, Pathological

    phase 3 mab completed

    1 trial

  16. VEGF Trap-Eye 2.0mg

    Regeneron UK Limited

    Macular Edema Secondary to Central Retinal Vein Occlusion

    phase 3 mab completed

    1 trial

  17. aflibercept

    Regeneron UK Limited

    Retinopathy of Prematurity

    phase 3 small molecule completed

    1 trial

  18. aflibercept 8 mg PFS

    Regeneron UK Limited

    Diabetic Macular Edema (DME)

    phase 3 small molecule completed

    1 trial

  19. alirocumab SAR236553 (REGN727)

    Regeneron UK Limited

    Hypercholesterolemia

    phase 3 small molecule completed

    8 trials

  20. alirocumab SAR236553 (REGN727)

    Regeneron UK Limited

    Hypercholesterolaemia

    phase 3 small molecule completed

    2 trials

  21. casirivimab+imdevimab

    Regeneron UK Limited

    Immunocompromised

    phase 3 small molecule terminated

    1 trial

  22. casirivimab+imdevimab combination therapy

    Regeneron UK Limited

    COVID-19

    phase 3 small molecule terminated

    1 trial

  23. cemiplimab

    Regeneron UK Limited

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    3 trials

  24. dupilumab

    Regeneron UK Limited

    Moderate to Severe Atopic Hand and Foot Dermatitis

    phase 3 small molecule completed

    1 trial

  25. dupilumab

    Regeneron UK Limited

    Bullous Pemphigoid

    phase 3 small molecule completed

    1 trial

  26. evinacumab

    Regeneron UK Limited

    Homozygous Familial Hypercholesterolemia

    phase 3 small molecule completed

    3 trials

  27. fianlimab

    Regeneron UK Limited

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  28. fianlimab

    Regeneron UK Limited

    Advanced Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  29. garetosmab

    Regeneron UK Limited

    Fibrodysplasia Ossificans Progressiva (FOP)

    phase 3 small molecule active

    1 trial

  30. garetosmab

    Regeneron UK Limited

    Fibrodyplasia Ossificans Progressiva (FOP)

    phase 3 small molecule terminated

    1 trial

  31. nexiguran ziclumeran

    Regeneron UK Limited

    Neuromuscular Disease

    phase 3 mab active

    1 trial

  32. rilonacept 160 mg

    Regeneron UK Limited

    Familial Cold Autoinflammatory Syndrome (FCAS)

    phase 3 small molecule completed

    1 trial

  33. sarilumab SAR153191 (REGN88)

    Regeneron UK Limited

    Rheumatoid Arthritis

    phase 3 small molecule completed

    6 trials

  34. ALN-ANG3

    Regeneron UK Limited

    Diabetic Kidney Disease (DKD)

    phase 2 small molecule active

    1 trial

  35. ALN-CFB

    Regeneron UK Limited

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 2 small molecule active

    1 trial

  36. ALN-CIDEB

    Regeneron UK Limited

    Metabolic Dysfunction-Associated Steatotic Liver Disease

    phase 2 small molecule active

    1 trial

  37. ALN-HSD

    Regeneron UK Limited

    Metabolic Dysfunction-Associated SteatoHepatitis (MASH)

    phase 2 small molecule active

    1 trial

  38. ALN-PNP

    Regeneron UK Limited

    Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

    phase 2 small molecule active

    1 trial

  39. ALN-PNP

    Regeneron UK Limited

    Healthy Volunteers

    phase 2 small molecule active

    1 trial

  40. ALN-SOD

    Regeneron UK Limited

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 small molecule active

    1 trial

  41. ARD6122

    Regeneron UK Limited

    Neoplasms

    phase 2 small molecule completed

    1 trial

  42. ARD6123

    Regeneron UK Limited

    Pulmonary Diseases

    phase 2 small molecule completed

    1 trial

  43. Aflibercept

    Regeneron UK Limited

    Proliferative Diabetic Retinopathy

    phase 2 small molecule completed

    1 trial

  44. Aflibercept

    Regeneron UK Limited

    Radiation Retinopathy

    phase 2 small molecule active

    1 trial

  45. Aflibercept

    Regeneron UK Limited

    Advanced Carcinoma

    phase 2 small molecule terminated

    1 trial

  46. Alirocumab

    Regeneron UK Limited

    Non Small Cell Lung Cancer

    phase 2 small molecule on hold

    1 trial

  47. Alirocumab

    Regeneron UK Limited

    Nephrotic Syndrome

    phase 2 small molecule terminated

    1 trial

  48. Alirocumab and Cemiplimab

    Regeneron UK Limited

    Non-small Cell Lung Cancer (NSCLC)

    phase 2 other active

    1 trial

Frequently asked questions

How many clinical projects does Regeneron UK have?

493 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.